These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 35802774)

  • 41. Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.
    Richine BM; Virts EL; Bowling JD; Ramdas B; Mali R; Naoye R; Liu Z; Zhang ZY; Boswell HS; Kapur R; Chan RJ
    Leukemia; 2016 Oct; 30(10):2094-2097. PubMed ID: 27256702
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer.
    Achkova D; Maher J
    Biochem Soc Trans; 2016 Apr; 44(2):333-41. PubMed ID: 27068937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Gene Expression Omnibus Database.
    Clough E; Barrett T
    Methods Mol Biol; 2016; 1418():93-110. PubMed ID: 27008011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor microenvironment and therapeutic response.
    Wu T; Dai Y
    Cancer Lett; 2017 Feb; 387():61-68. PubMed ID: 26845449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DNA repair, genome stability and cancer: a historical perspective.
    Jeggo PA; Pearl LH; Carr AM
    Nat Rev Cancer; 2016 Jan; 16(1):35-42. PubMed ID: 26667849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
    Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

  • 48. T cell exclusion, immune privilege, and the tumor microenvironment.
    Joyce JA; Fearon DT
    Science; 2015 Apr; 348(6230):74-80. PubMed ID: 25838376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Microenvironmental regulation of tumor progression and metastasis.
    Quail DF; Joyce JA
    Nat Med; 2013 Nov; 19(11):1423-37. PubMed ID: 24202395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling.
    Yang W; Wang J; Moore DC; Liang H; Dooner M; Wu Q; Terek R; Chen Q; Ehrlich MG; Quesenberry PJ; Neel BG
    Nature; 2013 Jul; 499(7459):491-5. PubMed ID: 23863940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.
    Hartman ZR; Schaller MD; Agazie YM
    Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
    Yokosuka T; Takamatsu M; Kobayashi-Imanishi W; Hashimoto-Tane A; Azuma M; Saito T
    J Exp Med; 2012 Jun; 209(6):1201-17. PubMed ID: 22641383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
    De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.
    Bard-Chapeau EA; Li S; Ding J; Zhang SS; Zhu HH; Princen F; Fang DD; Han T; Bailly-Maitre B; Poli V; Varki NM; Wang H; Feng GS
    Cancer Cell; 2011 May; 19(5):629-39. PubMed ID: 21575863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.
    Xu D; Wang S; Yu WM; Chan G; Araki T; Bunting KD; Neel BG; Qu CK
    Blood; 2010 Nov; 116(18):3611-21. PubMed ID: 20651068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune infiltration in human cancer: prognostic significance and disease control.
    Fridman WH; Galon J; Dieu-Nosjean MC; Cremer I; Fisson S; Damotte D; Pagès F; Tartour E; Sautès-Fridman C
    Curr Top Microbiol Immunol; 2011; 344():1-24. PubMed ID: 20512556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Microsatellite instability in colorectal cancer.
    Boland CR; Goel A
    Gastroenterology; 2010 Jun; 138(6):2073-2087.e3. PubMed ID: 20420947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.